NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)

NCT06079333 PHASE2 RECRUITING

Anaplastic thyroid cancer (ATC) is an almost invariable lethal cancer in humans. Most patients present with a rapid progressive mass in the neck with progressive complaints like dyspnoea, dysphagia or pain. The risk of suffocation is the main reason for rapid surgical intervention, but we know from literature that an oncological resection with clear margins is seldomly achieved. Some patients deteriorate that fast after surgery that radiation therapy and/or chemotherapy is not feasible anymore. Patients with BRAF-mutated ATC already have shown to benefit from targeted BRAF/MEK inhibition. This study aims to increase the number of patients that undergo a successful R0 tumor resection after neo-adjuvant BRAF/MEK inhibitor treatment.

Details

Lead sponsor	Leiden University Medical Center
Phase	PHASE2
Status	RECRUITING
Enrolment	20
Start date	Sun Jan 01 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sat Jan 01 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Anaplastic Thyroid Cancer

Interventions

• dabrafenib/trametinib

Countries

Netherlands